Contact us Demo our platform

Case Study

Understanding VLCAD Deficiency

Metabolon offered this group the most comprehensive solution for characterizing the metabolic differences between fasting individuals and patients with VLCAD deficiency.

This study demonstrates that untargeted metabolomics data from plasma can distinguish patients with a normal physiologic response to fasting versus patients with VLCAD deficiency, Specifically, the generalized elevation of acylcarnitines observed in physiologic fasting is distinguishable from the more localized and dramatic increase in C14:1 and longer chain length acylcarnitine species in VLCAD deficiency.

Talk With An Expert About Your Project

This study demonstrates that untargeted metabolomics data from plasma can distinguish patients with a normal physiologic response to fasting versus patients with VLCAD deficiency, Specifically, the generalized elevation of acylcarnitines observed in physiologic fasting is distinguishable from the more localized and dramatic increase in C14:1 and longer chain length acylcarnitine species in VLCAD deficiency.

Talk With An Expert About Your Project
Understanding VLCAD Deficiency

The Challenge: Better Diagnosis for Patients with VLCAD Deficiency

Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is a rare genetic disease that prevents the body from properly converting long-chain fatty acids into energy. The phenotype associated with VLCAD deficiency is very heterogeneous. Mild symptoms may include low blood sugar, poor appetite, lack of energy, and muscle weakness in early childhood. In severe cases, VLCAD may present with neonatal cardiomyopathy, hypoglycemia, hepatic dysfunction, multiorgan failure, and death. High levels of C14:1 acylcarnitine in dried blood spots (DBS) are typically the primary analyte for newborn screening (NBS) of VLCAD deficiency. However, there are still limitations in confirming abnormal NBS by biochemical testing alone. More advanced molecular testing has been recommended as second-tier testing before diagnosing a patient with an abnormal NBS for VLCAD deficiency. A challenge that limits NBS to detect VLCAD deficiency is that increases in plasma acylcarnitine levels have also been observed in fasted individuals. Metabolomics could help distinguish fasted patients without VLCAD deficiency from patients with VLCAD deficiency.

Metabolon Insight: Deciphering Metabolic Differences Between Fasted Individuals and Patients with VLCAD Deficiency

This study utilized the Metabolon Global Discovery Panel to profile the plasma of one patient with VLCAD deficiency and two individuals after a 24-hour fast.1 Metabolon Global Discovery Panel‘s unrivaled coverage of up to 5,400 semi-quantifiable metabolites offered this group the most comprehensive solution for characterizing the metabolic differences between fasting individuals and patients with VLCAD deficiency.

The Solution: Metabolomics Reveals Differences in Lipid Metabolism

In this study, to determine whether C14:1 and C14:2 elevations that result from fasting can be distinguished from C14:1 and C14:2 elevations that result from VLCAD deficiency, the research group compared plasma acylcarnitine profiles and metabolomics data from two fasted subjects versus an individual with VLCAD deficiency. Targeted metabolomics of plasma acylcarnitines demonstrated that patients with VLCAD deficiency have significantly greater ratios of C14:1/C12:1 compared to fasted patients.

Analysis of the untargeted metabolomics data revealed numerous differences in lipid metabolism between the two groups but similar glucose levels. Fasted individuals had high levels of multiple free and dicarboxylic fatty acids, whereas only the monosaturated fatty acid, myristoleate (C14:1), was significantly elevated in the patient with VLCAD deficiency. Long-chain acyl-carnitine conjugates were elevated in all patients, but the elevation was more striking in the patient with VLCAD deficiency. In contrast, the ketone bodies, 3-hydroxybutyrate and acetoacetate, were much more highly elevated in fasting individuals than in patients with VLCAD deficiency.

The Outcome: Metabolomics May Improve Diagnoses of VLCAD Deficiency

When presented with a patient with elevated C14:1 (acylcarnitine) in plasma, this study suggests that C14:1/C12:1 may be a valuable indicator to distinguish physiologic elevations of C14:1 from fasting versus VLCAD deficiency. This study also shows that untargeted metabolomics data in plasma can distinguish patients with a normal physiologic response to fasting versus patients with VLCAD deficiency.

References

1. Burrage LC, Miller MJ, Wong LJ, et al. Elevations of C14:1 and C14:2 Plasma Acylcarnitines in Fasted Children: A Diagnostic Dilemma. J Pediatr. Feb 2016;169:208-13.e2. doi:10.1016/j.jpeds.2015.10.045

Related Case Studies

See All Case Studies
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.